Sugi Predict

Sugi Predict / Compounds / SCHEMBL534956

SCHEMBL534956

SCHEMBL534956

Cc1cc(Cl)nc(Cl)c1C#N

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 1/20 0.57
▸ KDM4E B2RXH2 7/20 0.46
▸ ALDH1A1 P00352 4/20 0.46
▸ KMT2A Q03164 2/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ RECQL P46063 3/20 0.42
▸ CYP1A2 P05177 1/20 0.41
▸ CYP2C9 P11712 1/20 0.41
▸ CYP2C19 P33261 1/20 0.41
▸ POLB P06746 3/20 0.40
▸ MAPT P10636 2/20 0.40
▸ XBP1 P17861 2/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.40
▸ GLA P06280 2/20 0.40
▸ HSD17B10 Q99714 2/20 0.40
▸ GAA P10253 1/20 0.40
▸ NPSR1 Q6W5P4 1/20 0.40
▸ TSHR P16473 1/20 0.40
▸ MAPK1 P28482 2/20 0.39
▸ NSD2 O96028 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29496331 1.00 L3MBTL1 (0.57) L3MBTL1KDM4EALDH1A1KMT2AMEN1
SCHEMBL4067248 0.87 RECQL (0.59) L3MBTL1KDM4EALDH1A1KMT2AMEN1
SCHEMBL4071512 0.85 L3MBTL1 (0.46) L3MBTL1KDM4EALDH1A1KMT2AMEN1
SCHEMBL10074682 0.83 KDM4E (0.46) L3MBTL1KDM4EALDH1A1KMT2AMEN1
SCHEMBL318407 0.83 KDM4E (0.60) L3MBTL1KDM4EALDH1A1KMT2AMEN1
SCHEMBL29420807 0.83 KDM4E (0.60) L3MBTL1KDM4EALDH1A1KMT2AMEN1
SCHEMBL18704062 0.82 KDM4E (0.54) L3MBTL1KDM4EALDH1A1KMT2AMEN1
SCHEMBL11845115 0.80 KDM4E (0.67) L3MBTL1KDM4EALDH1A1KMT2AMEN1
SCHEMBL3832490 0.80 KDM4E (0.43) L3MBTL1KDM4EALDH1A1KMT2AMEN1
SCHEMBL3639155 0.80 L3MBTL1 (0.54) L3MBTL1KDM4EALDH1A1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 566 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117511248-A Preparation method of solvent orange 116 宜昌思创新材料科技有限公司 2024-02-06 — — CN claimed
CN-111153825-A Method for preparing amide compound by using supported metal oxide catalytic material 浙江大学 2020-05-15 — — CN claimed
CN-109096182-A A kind of preparation method of nevirapine intermediate 湖北宇阳药业有限公司 2018-12-28 — — CN claimed
US-5668287-A Method for the preparation of 3-amino-2-chloro-4-methylpyridines BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 1997-09-16 — — US claimed
EP-0543000-B1 NOVEL METHOD FOR PREPARING 3-AMINO-2-CHLORO-4-ALKYLPYRIDINES BOEHRINGER INGELHEIM PHARMA (US) 1996-12-11 — — EP claimed
EP-0551459-B1 METHOD FOR THE PREPARATION OF 3-AMINO-2-CHLORO-4-ALKYLPYRIDINES BOEHRINGER INGELHEIM PHARMA (US) 1996-11-20 — — EP claimed
EP-0551459-A4 — — 1994-03-16 — — EP claimed
EP-0543000-A4 — — 1994-03-16 — — EP claimed
EP-0551459-A1 METHOD FOR THE PREPARATION OF 3-AMINO-2-CHLORO-4-ALKYLPYRIDINES. BOEHRINGER INGELHEIM PHARMA (US) 1993-07-21 — — EP claimed
EP-0543000-A1 NOVEL METHOD FOR PREPARING 3-AMINO-2-CHLORO-4-ALKYLPYRIDINES. BOEHRINGER INGELHEIM PHARMA (US) 1993-05-26 — — EP claimed
WO-1992022532-A1 NOVEL METHOD FOR PREPARING 3-AMINO-2-CHLORO-4-ALKYLPYRIDINES BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 1992-12-23 — — WO claimed
WO-1992022531-A1 METHOD FOR THE PREPARATION OF 3-AMINO-2-CHLORO-4-ALKYLPYRIDINES BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 1992-12-23 — — WO claimed
EP-4743462-A1 COMPOUNDS COMPRISING A NAPHTHYRIDINE OR PYRIDOPYRIMIDINE CORE AS PTC READ-THROUGH AGENTS Tay Therapeutics Limited (GB) 2026-05-20 — — EP disclosed
US-12583852-B2 Heterocycle derivative JW PHARMACEUTICAL CORPORATION (KR) 2026-03-24 — — US disclosed
US-20260055116-A1 SUBSTITUTED TETRAHYDROPYRROLO-PYRIDINONE COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS KARUNA THERAPEUTICS INC (US) 2026-02-26 — — US disclosed
US-20260007642-A1 INHIBITORS OF SHORT-CHAIN DEHYDROGENASE ACTIVITY FOR PROMOTING NEUROGENESIS AND INHIBITING NERVE CELL DEATH UNIV CASE WESTERN RESERVE (US) 2026-01-08 — — US disclosed
US-3954782-A 2,6-Hydrazino-3-pyridine carboxyamides CASSELLA FARBWERKE MAINKUR AKTIENGESELLSCHAFT (DT) 1976-05-04 — — US disclosed
US-3950321-A POLYESTERS BASF AKTIENGESELLSCHAFT (DT) 1976-04-13 — — US disclosed
US-3947463-A Certain 2-amino-nicotinonitrile derivatives CASSELLA FARBWERKE MAINKUR AG (DT) 1976-03-30 — — US disclosed
US-3946024-A INTERMEDIATES FOR AZO DYES CASSELLA FARBWERKE MAINKUR AG (DT) 1976-03-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12583852-B2 Heterocycle derivative AR, SRD5A1, NR5A1 L3MBTL1 3665/4885KDM4E 413/4885ALDH1A1 1733/4885
US-20260007642-A1 INHIBITORS OF SHORT-CHAIN DEHYDROGENASE ACTIVITY FOR PROMOTING NEUROGENESIS AND INHIBITING NERVE CELL DEATH PTGDR, HPGD, PTGDR2 L3MBTL1 4312/4885KDM4E 3195/4885ALDH1A1 110/4885
US-20260055116-A1 SUBSTITUTED TETRAHYDROPYRROLO-PYRIDINONE COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS CHRM3, CHRM2, CHRM1 L3MBTL1 2918/4885KDM4E 4067/4885ALDH1A1 704/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.